Crane Advisory LLC Sells 882 Shares of Johnson & Johnson (NYSE:JNJ)

Crane Advisory LLC lessened its position in shares of Johnson & Johnson (NYSE:JNJ) by 8.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 9,825 shares of the company’s stock after selling 882 shares during the period. Johnson & Johnson makes up about 0.2% of Crane Advisory LLC’s holdings, making the stock its 17th biggest position. Crane Advisory LLC’s holdings in Johnson & Johnson were worth $1,417,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. 180 Wealth Advisors LLC increased its holdings in shares of Johnson & Johnson by 7.1% in the 4th quarter. 180 Wealth Advisors LLC now owns 14,292 shares of the company’s stock worth $2,067,000 after buying an additional 953 shares during the last quarter. Capital CS Group LLC bought a new position in shares of Johnson & Johnson in the 4th quarter worth $204,000. West Oak Capital LLC increased its holdings in shares of Johnson & Johnson by 1.5% in the 4th quarter. West Oak Capital LLC now owns 16,018 shares of the company’s stock worth $2,316,000 after buying an additional 230 shares during the last quarter. Signal Advisors Wealth LLC increased its holdings in shares of Johnson & Johnson by 5.6% in the 4th quarter. Signal Advisors Wealth LLC now owns 7,969 shares of the company’s stock worth $1,152,000 after buying an additional 420 shares during the last quarter. Finally, Johnson & White Wealth Management LLC bought a new position in shares of Johnson & Johnson in the 4th quarter worth $1,234,000. Institutional investors own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In related news, Director Mark A. Weinberger bought 1,000 shares of the company’s stock in a transaction dated Thursday, December 12th. The stock was purchased at an average cost of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 0.1 %

Shares of JNJ opened at $144.68 on Wednesday. The stock has a market capitalization of $348.33 billion, a P/E ratio of 20.94, a PEG ratio of 2.52 and a beta of 0.51. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The firm has a fifty day simple moving average of $149.12 and a two-hundred day simple moving average of $156.09. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. During the same quarter in the prior year, the company posted $2.66 EPS. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. On average, research analysts anticipate that Johnson & Johnson will post 9.94 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.43%. Johnson & Johnson’s dividend payout ratio is 71.78%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on JNJ. Morgan Stanley increased their price target on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Wolfe Research assumed coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They set an “outperform” rating and a $190.00 target price on the stock. Wells Fargo & Company increased their target price on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Royal Bank of Canada increased their target price on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a report on Wednesday, October 16th. Finally, Bank of America reaffirmed a “neutral” rating and set a $166.00 target price on shares of Johnson & Johnson in a report on Tuesday, December 10th. Seven research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $174.71.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.